A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors

被引：0
|
作者：
Sausville, E. [1 ,2 ,3 ,4 ,5 ]
Garbo, L. [1 ,2 ,3 ,4 ,5 ]
Weiss, G. J. [1 ,2 ,3 ,4 ,5 ]
Anthony, S. [1 ,2 ,3 ,4 ,5 ]
Shkolny, D. [1 ,2 ,3 ,4 ,5 ]
Yurkovetskiy, A. V. [1 ,2 ,3 ,4 ,5 ]
Bethune, C. [1 ,2 ,3 ,4 ,5 ]
Fram, R. J. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] New York Oncol Hematol, Albany, NY USA
[3] TGen, Clin Res Serv, Scottsdale, AZ USA
[4] Mersana Therapeut Inc, Cambridge, MA USA
[5] Covance Bioanalyt, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2574
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I study of XMT-1001 given IV every 3 weeks to patients with advanced solid tumors
    Sausville, E. A.
    Garbo, L. E.
    Weiss, G. J.
    Shkolny, D.
    Yurkovetskiy, A. V.
    Bethune, C.
    Ramanathan, R. K.
    Fram, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Phase I study of XMT-1001, a novel water soluble camptothecin conjugate, given as an intravenous infusion once every three weeks to patients with advanced solid tumors
    Sausville, Edward A.
    Garbo, Lawrence
    Weiss, Glen J.
    Shkolny, Dana
    Yurkovetskiy, Alexander V.
    Bethune, Claudette
    Ramanathan, Ramesh K.
    Fram, Robert J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [3] A phase I study of the safety, tolerability, and pharmacokinetics of intravenous XMT-1001 in patients with advanced solid tumors
    Sausville, Edward A.
    Anthony, Stephen P.
    Garbo, Lawrence E.
    Shkolny, Dana
    Yurkovetskiy, Alex V.
    Bethune, Claudette
    Schwertschlag, Ullrich
    Fram, Robert J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3383S - 3383S
  • [4] Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an IV infusion every 3 weeks to patients with advanced solid tumors
    Fram, R. J.
    Garbo, L. E.
    Weiss, G. J.
    Shkolny, D.
    Yurkovetskiy, A. V.
    Bethune, C.
    Ramanathan, R. K.
    Edelman, M. J.
    Sausville, E. A.
    EJC SUPPLEMENTS, 2010, 8 (07): : 180 - 180
  • [5] A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors
    Rademaker-Lakhai, JM
    Terret, C
    Howell, SB
    Baud, CM
    de Boer, RF
    Pluim, D
    Beijnen, JH
    Schellens, JHM
    Droz, JP
    CLINICAL CANCER RESEARCH, 2004, 10 (10) : 3386 - 3395
  • [6] Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
    Massard, C.
    Salazar, R.
    Armand, J. P.
    Majem, M.
    Deutsch, E.
    Garcia, M.
    Oaknin, A.
    Fernandez-Garcia, E. M.
    Soto, A.
    Soria, J. C.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2318 - 2326
  • [7] Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
    C. Massard
    R. Salazar
    J. P. Armand
    M. Majem
    E. Deutsch
    M. García
    A. Oaknin
    E. M. Fernández-García
    A. Soto
    J. C. Soria
    Investigational New Drugs, 2012, 30 : 2318 - 2326
  • [8] Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
    Papadopoulos, K. P.
    Chu, Q.
    Patnaik, A.
    Mita, M. M.
    Cooper, J.
    Van Maanen, R.
    Lopez-Lazaro, L.
    Lebedinsky, C.
    Rowinsky, E. K.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 86S - 86S
  • [9] Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
    Sessa, Cristiana
    Del Conte, Gianluca
    Christinat, Alexandre
    Cresta, Sara
    Perotti, Antonella
    Gallerani, Elisa
    Lardelli, Pilar
    Kahatt, Carmen
    Alfaro, Vicente
    Iglesias, Jorge L.
    Fernandez-Teruel, Carlos
    Gianni, Luca
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1236 - 1243
  • [10] Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
    Cristiana Sessa
    Gianluca Del Conte
    Alexandre Christinat
    Sara Cresta
    Antonella Perotti
    Elisa Gallerani
    Pilar Lardelli
    Carmen Kahatt
    Vicente Alfaro
    Jorge L. Iglesias
    Carlos Fernández-Teruel
    Luca Gianni
    Investigational New Drugs, 2013, 31 : 1236 - 1243
12345